Your Search for 'Non-Small Cell Lung Cancer - Avastin to Lead the Market' returned 6 results - Page 1 of 1

• AVEO Pharmaceuticals’ and Astellas Pharma’s Tivozanib - Can this angiogenesis inhibitor distinguish itself from the field?

  EURO€ 1,153.00USD$ 1,500.00GBP£ 970.00AUD$ 1,467.00JPY¥ 148,099.00SEK 9 849,00CHF 1'414.00CAD$ 1,528.00 LifeTech Research, Jul 2011 , Pages: 37
  plus Taxol (paclitaxel) in advanced breast cancer - Tivozanib monotherapy in advanced non-small cell lung cancer (NSCLC) - Tivozanib plus Afinitor (everolimus) in advanced colorectal cancer - Tivozanib ...

• Cancer Therapies - Global Strategic Business Report

  EURO€ 3,982.00USD$ 4,500.00GBP£ 2,655.00AUD$ 6,223.00JPY¥ 539,634.00SEK 35 400,00CHF 5'926.00CAD$ 5,772.00 Global Industry Analysts, Inc, Oct 2011 , Pages: 897
  indicated for the treatment of non-small cell lung cancer, and Avastin, and Paclitaxel combo for treating metastatic breast cancer. Monoclonal Antibodies (mAbs), which find use in immunotherapeutics and ...

• Angiogenesis Inhibitors and Stimulators - Global Business Strategic Report

  EURO€ 4,381.00USD$ 4,950.00GBP£ 2,920.00AUD$ 6,845.00JPY¥ 593,598.00SEK 38 940,00CHF 6'519.00CAD$ 6,349.00 Global Industry Analysts, Inc, May 2012 , Pages: 675
  Approved by FDA for Dermatology II-27 3. MARKET TRENDS II-28 Cancer - The Key Target Indication for Research in Anti- Angiogeneis Drugs II-28 Avastin Continues to Record Robust Growth II-28 New ...

• Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities

  EURO€ 3,622.00USD$ 4,093.00GBP£ 2,415.00AUD$ 5,660.00JPY¥ 490,854.00SEK 32 200,00CHF 5'391.00CAD$ 5,250.00 Spectra Intelligence, Apr 2006 , Pages: 369
  chemotherapies are on course for staggering growth potential and may revolutionize cancer treatments over the next 10 years according to a new report from biopharma market research publisher, Spectra Intelligence ...

• Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success

  EURO€ 2,400.00USD$ 2,712.00GBP£ 1,600.00AUD$ 3,750.00JPY¥ 325,203.00SEK 21 333,00CHF 3'571.00CAD$ 3,478.00 Spectra Intelligence, Nov 2006 , Pages: 367
  Immunotherapy Approaches to Cancer Figure 3.5 Construction of Human Monoclonal Antibodies Using the Method of Phage Display Figure 4.1 General Cell Pathways that Contain Oncogenic Targets for Small Molecule ...

• Top 7 Cancer Indications - Therapeutic & Competitive Insights

  EURO€ 5,560.00USD$ 7,233.00GBP£ 4,678.00AUD$ 7,075.00JPY¥ 714,175.00SEK 47 493,00CHF 6'818.00CAD$ 7,371.00 Bioseeker, Jan 2007 , Pages: 750
  published evaluating therapeutic and competitive insights in the anti-cancer arena. The report is structured according to the top 7 cancer indications: Breast cancer, Colon/colorectal cancer, Leukemia, Lung ...